15/01/2026
Cyclana Bio, a pioneering company in women’s health and part of the Accelerate@Babraham 2025 cohort, has taken a significant step forward in its mission to find a cure for endometriosis. The company has announced the appointment of their Chief Technology Officer (CTO), Jonathan Griffiths, adding significant technical expertise as it accelerates the development of its innovative research.
Back in July, Cyclana Bio outlined an ambitious roadmap during the Accelerate@Babraham demo day: to collect patient data, validate its models and preliminary targets, and expand laboratory capabilities over the next 18 months. While being based in LiveLabs at Babraham Research Campus, the team has already begun collecting menstrual fluid with the goal of making better cellular models of women’s health in the lab.
Léa Wenger, Co-Founder & CEO of Cyclana Bio, said: "Accelerate@Babraham was pivotal to us being able to move so fast. The networks it enabled and importantly the work it allowed us to do in the lab meant not only that we were able to fundraise quickly, but also that once we had fundraised, we were already set up to get results!"
The addition of a CTO marks a pivotal moment in Cyclana Bio’s growth. Jonathan will lead the company’s computational efforts, strengthening its ability to scale research and accelerate discovery. By strengthening its leadership team, Cyclana Bio is well-positioned to advance its research and deliver transformative solutions for those affected by endometriosis and related conditions.
Founded by Léa Wenger and Kevin Chalut, Cyclana Bio emerged from a shared passion for scientific innovation and a personal connection to the challenges of women’s health. With this latest milestone, the company continues to demonstrate its commitment to close the gender health gap and bring innovation to a long-stagnant field.